Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc (NQ: LTRN )

5.770 -0.220 (-3.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 107,146
Open 5.920
Bid (Size) 5.570 (5)
Ask (Size) 5.750 (34)
Prev. Close 5.990
Today's Range 5.750 - 6.130
52wk Range 2.380 - 11.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
EQNX::TICKER_START (OTCQB:TREIF),(CSE:TRUE),(NYSE:MDT),(NASDAQ:NVDA),(NASDAQ:LTRN),(OTCQX:HWAIF),(TSX:AIDX) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety

Performance

YTD
+38.37%
+38.37%
1 Month
-22.96%
-22.96%
3 Month
+50.26%
+50.26%
6 Month
+86.73%
+86.73%
1 Year
+15.40%
+15.40%

More News

Read More
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recap: Lantern Pharma Q4 Earnings
Via Benzinga
Lantern Pharma Earnings Preview
Via Benzinga
Six Of Seven AI Stock Categories Increased This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
From FN Media Group LLC
Via GlobeNewswire
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
Via InvestorPlace
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
Earnings Scheduled For March 18, 2024
Via Benzinga
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
From Lantern Pharma Inc.
Via Business Wire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Via Talk Markets
3 AI Powerhouses Predicted to Soar 500% in the Next Tech Boom
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
From Lantern Pharma Inc.
Via Business Wire
Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
From Lantern Pharma
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.